INVESTINGSangamo Shares Soar as Hemophilia Drug Shows PromiseBy Scott Van VoorhisJul 8, 2019 11:10 AM EDT
INVESTINGRoche Buys More Time in $4.3B Offer for Spark TherapeuticsBy M. Corey GoldmanApr 3, 2019 9:43 AM EDT
STOCKSTrading Roku Stock as Downgrades Sap Its Run to New HighsBy Bret KenwellMar 13, 2019 1:20 PM EDT
JIM CRAMERWin, With or Without China: Cramer's 'Mad Money' RecapBy Scott RuttFeb 25, 2019 8:57 PM EST
MARKETS3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo AltoBy Jacob SonenshineFeb 25, 2019 4:19 PM EST
MARKETSDow Closes Modestly Higher After Trump Extends China Tariff DeadlineBy Joseph WoelfelFeb 25, 2019 4:06 PM EST
STOCKSSpark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy ExpertsBy Martin BaccardaxFeb 25, 2019 11:37 AM EST
MARKETSTrade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must KnowBy Joseph WoelfelFeb 25, 2019 8:05 AM EST
STOCKSStocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk ProgressBy Martin BaccardaxFeb 25, 2019 7:37 AM EST
MARKETSRoche Aims to Buy Spark for $5 Billion: Wall Street JournalBy Adam SmithFeb 24, 2019 12:45 PM EST
STOCKS7 Winners and Losers From Biggest Biotech Conference of 2017By Tony OwusuDec 13, 2017 11:34 AM EST
STOCKSBluebird Bio Becoming Household Name With This Promising Cancer TreatmentBy Bret KenwellDec 11, 2017 12:23 PM EST
REGULATIONFDA Advisory Committee Greenlights First Gene Therapy For Inherited DisorderBy Bill MeagherOct 12, 2017 7:26 PM EDT
HEALTHIllumina Shares Jump on Better-Than-Expected Second-Quarter NumbersBy Armie Margaret LeeAug 2, 2017 11:17 AM EDT
HEALTHCelgene, Vertex and Spark Among Jefferies' Top Biotech PicksBy Armie Margaret LeeJul 14, 2017 4:11 PM EDT
STOCKSBlood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 MeetingBy Adam FeuersteinDec 5, 2016 1:11 PM EST
STOCKSSpark's hemophilia gene therapy remains effective despite immune reactionsBy Adam FeuersteinDec 3, 2016 1:04 PM EST
STOCKSThe Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do SameBy Adam FeuersteinNov 3, 2016 10:31 AM EDT
OPINIONJim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, CampbellBy Scott RuttSep 9, 2016 6:00 AM EDT
JIM CRAMERJim Cramer's 'Mad Money' Recap: This Market Has a One-Track MindBy Scott RuttSep 8, 2016 8:16 PM EDT
OPINION13 companies to watch from MIT's smart 50 list, including 4 buysBy Robert WassermanJul 21, 2016 7:48 AM EDT
MARKETSStrong On High Relative Volume: Spark Therapeutics (ONCE)By TheStreet WireJul 12, 2016 10:02 AM EDT
JIM CRAMER'Mad Money' Lightning Round: You Should Own General ElectricBy Scott RuttJun 30, 2016 6:00 AM EDT
